康臣药业：上半年权益股东应占溢利同比增约24.6%

Group 1 - The core viewpoint of the article is that 康臣药业 reported significant revenue and profit growth for the six months ending June 30, 2025, indicating strong financial performance [1] Group 2 - The company's revenue for the period reached RMB 1.569 billion, representing a year-on-year increase of approximately 23.7% [1] - The profit attributable to equity shareholders was RMB 498 million, reflecting a year-on-year increase of about 24.6% [1]